Literature DB >> 10613720

Cholangiocarcinoma in patients with primary sclerosing cholangitis: a multicenter case-control study.

N Chalasani1, A Baluyut, A Ismail, A Zaman, G Sood, R Ghalib, T M McCashland, K R Reddy, X Zervos, M A Anbari, H Hoen.   

Abstract

Patients with primary sclerosing cholangitis (PSC) have a significantly increased risk of developing cholangiocarcinoma (CCA). Risk factors for developing such a complication are not well defined. We conducted a multicenter, case-control study to determine the risk factors and possible predictors for CCA in patients with PSC. The demographic, clinical, and laboratory features of 26 PSC patients with CCA diagnosed over a 7-year period at eight academic centers were compared with 87 patients with PSC but no CCA (controls). There was no statistically significant difference in demographics, smoking, signs or symptoms or complications of PSC, indices of disease severity (Mayo Risk score or Child-Pugh score), frequency or duration or complications of inflammatory bowel disease (IBD), frequency of biliary surgery, or therapeutic endoscopy between the two groups. Alcohol consumption was significantly associated with CCA in patients with PSC (odds ratio: 2.95; 95% CI: 1.04-8.3). Serum carbohydrate antigen 19-9 (CA 19-9) was significantly higher in patients with CCA than those without (177 +/- 89 and 61 +/- 58 U/mL, respectively; P =.002). A serum CA 19-9 level > 100 U/mL had 75% sensitivity and 80% specificity in identifying PSC patients with CCA. In conclusion, alcohol consumption was a risk factor for having CCA in PSC patients. The indices of severity of liver disease were not associated with CCA in patients with PSC. Serum CA 19-9 appeared to have good ability to discriminate PSC patients with and without CCA.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10613720     DOI: 10.1002/hep.510310103

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  73 in total

Review 1.  Current therapies and clinical controversies in the management of primary sclerosing cholangitis.

Authors:  R T Prall; K D Lindor; R H Wiesner; N F LaRusso
Journal:  Curr Gastroenterol Rep       Date:  2000-04

2.  Utility of serum CA19-9 in diagnosis of cholangiocarcinoma: in comparison with CEA.

Authors:  Xing-Lei Qin; Zhuo-Ren Wang; Jing-Sen Shi; Min Lu; Lin Wang; Quan-Ru He
Journal:  World J Gastroenterol       Date:  2004-02-01       Impact factor: 5.742

3.  Endoscopic treatment of biliary tract disease prior to orthotopic liver transplantation.

Authors:  Roshan Shrestha; David M S Grunkemeier
Journal:  Curr Treat Options Gastroenterol       Date:  2006-04

4.  A nuclear receptor ligand down-regulates cytosolic phospholipase A2 expression to reduce bile acid-induced cyclooxygenase 2 activity in cholangiocytes: implications of anticarcinogenic action of farnesoid X receptor agonists.

Authors:  Daisuke Komichi; Susumu Tazuma; Tomoji Nishioka; Hideyuki Hyogo; Kazuaki Chayama
Journal:  Dig Dis Sci       Date:  2005-03       Impact factor: 3.199

Review 5.  Cholangiocarcinoma in primary sclerosing cholangitis.

Authors:  Ghulam Abbas; Keith D Lindor
Journal:  J Gastrointest Cancer       Date:  2009-08-25

Review 6.  Cholangiocarcinoma.

Authors:  Nataliya Razumilava; Gregory J Gores
Journal:  Lancet       Date:  2014-02-26       Impact factor: 79.321

Review 7.  Primary sclerosing cholangitis: detection of cancer in strictures.

Authors:  Richard D Schulick
Journal:  J Gastrointest Surg       Date:  2007-11-13       Impact factor: 3.452

8.  Immunohistochemical study of DPC4 and p53 proteins in gallbladder and bile duct cancers.

Authors:  Shih-Chang Chuang; King-Teh Lee; Kun-Bow Tsai; Pai-Ching Sheen; Eishi Nagai; Kazuhiro Mizumoto; Masao Tanaka
Journal:  World J Surg       Date:  2004-09-29       Impact factor: 3.352

Review 9.  Diagnosis and management of primary sclerosing cholangitis-perspectives from a therapeutic endoscopist.

Authors:  Kunjam Modha; Udayakumar Navaneethan
Journal:  World J Hepatol       Date:  2015-04-18

10.  Carcinoembryonic Antigen Level in Primary Sclerosing Cholangitis Is Not Influenced by Dominant Strictures or Bacterial Cholangitis.

Authors:  Andreas Wannhoff; Christian Rupp; Kilian Friedrich; Johannes Knierim; Christa Flechtenmacher; Karl Heinz Weiss; Wolfgang Stremmel; Daniel N Gotthardt
Journal:  Dig Dis Sci       Date:  2016-12-09       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.